A practical reference on Chromatographic purity: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-07 and is reviewed periodically as new material appears.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human therapeutic use | No marketing authorization identified in major jurisdictions. |
| Anti-doping class | PPARδ agonist; hormone and metabolic modulators | Listed on the WADA Prohibited List. |
| Common test matrix | Urine | Also blood and tissue in research settings. |
| Typical analytical method | LC-MS/MS | Targets parent compound and metabolites. |
| Major safety signal | Tumor findings in rodents | Human relevance not established; limited human data. |
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
== Isolation == Veratridine has been isolated from the seeds of Schoenocaulon officinale and from the rhizomes of Veratrum album. Like the other steroidal alkaloids found in these plants and similar ones in the Melanthiaceae family, it is present as part of a glycosidal combination, bonded to carbohydrate moieties. Early isolation methods relied on formation of the nitrate salt and then precipitation of the insoluble sulfate form. Accounts of these efforts date back to 1878, but the first true purification of veratridine is the one carried out in 1953 by Kupchan et al. This, and later purification procedures, begin with veratrine, a mixture of the alkaloids present in the Veratrum plants, primarily containing cevadine and veratridine. The nitrate salt is formed by dissolving the veratrine in 1% sulfuric acid over ice and precipitating with sodium nitrate. After resuspending in water over ice, the solution is brought to pH 8.5 with aqueous NaOH and then pH 10 with aqueous ammonia, forming another precipitate which is extracted with ether and then with chloroform. The ether and chloroform fractions are combined and dried. The dried residue is dissolved in sulfuric acid and the sulfate salt of veratridine is precipitated by dropwise addition of a solution of ammonium sulfate. Finally, the free base form is generated with ammonium hydroxide.
==== Methodological issues in studies ==== Knowledge about the pharmacokinetics of oral progesterone has been complicated by the use of flawed analytical techniques. When progesterone is taken orally, due to first-pass metabolism, very high levels of its metabolites occur. Most previous studies have used a method known as immunoassay (IA) to measure progesterone levels. However, IA without chromatographic separation (CS) has high cross-reactivity and is unable to differentiate between progesterone and metabolites such as allopregnanolone and pregnanolone. As a result, studies that have assessed the pharmacokinetics of oral progesterone using IA have reported falsely high progesterone levels and inaccurate dependent pharmacokinetic parameters. Comparative studies using reliable and exact methods such as liquid chromatography–mass spectrometry (LC–MS) and IA in conjunction with adequate CS have found that IA without CS overestimates levels of progesterone by 5- to 8-fold. For this reason, the use of reliable assays is mandatory when studying the pharmacokinetics of oral progesterone, and an awareness of these methodological issues is likewise essential for an accurate understanding of the pharmacokinetics of oral progesterone. Conversely, the same issues are not applicable to parenteral routes of progesterone such as vaginal administration and intramuscular injection, because these routes are not subject to a first pass and relatively low levels of progesterone metabolites are formed.
=== Evolutionary mechanism of compensation === Compensatory mutations can be explained by the genetic phenomenon epistasis whereby the phenotypic effect of one mutation is dependent upon mutation(s) at other loci. While epistasis was originally conceived in the context of interaction between different genes, intragenic epistasis has also been studied recently. Existence of compensated pathogenic deviations can be explained by 'sign epistasis', in which the effects of a deleterious mutation can be compensated by the presence of an epistatic mutation in another loci. For a given protein, a deleterious mutation (D) and a compensatory mutation (C) can be considered, where C can be in the same protein as D or in a different interacting protein depending on the context. The fitness effect of C itself could be neutral or somewhat deleterious such that it can still exist in the population, and the effect of D is deleterious to the extent that it cannot exist in the population. However, when C and D co-occur together, the combined fitness effect becomes neutral or positive. Thus, compensatory mutations can bring novelty to proteins by forging new pathways of protein evolution : it allows individuals to travel from one fitness peak to another through the valleys of lower fitness. DePristo et al. 2005 outlined two models to explain the dynamics of compensatory pathogenic deviations (CPD). In the first hypothesis P is a pathogenic amino acid mutation that and C is a neutral compensatory mutation.
A flow of argon gas (usually 13 to 18 liters per minute) is introduced between the two outermost tubes of the torch and an electric spark is applied for a short time to introduce free electrons into the gas stream. These electrons interact with the radio-frequency magnetic field of the induction coil and are accelerated first in one direction, then the other, as the field changes at high frequency (usually 27.12 million cycles per second). The accelerated electrons collide with argon atoms, and sometimes a collision causes an argon atom to part with one of its electrons. The released electron is in turn accelerated by the rapidly changing magnetic field. The process continues until the rate of release of new electrons in collisions is balanced by the rate of recombination of electrons with argon ions (atoms that have lost an electron). This produces a ‘fireball’ that consists mostly of argon atoms with a rather small fraction of free electrons and argon ions. The temperature of the plasma is very high, of the order of 10,000 K. The plasma also produces ultraviolet light, so for safety should not be viewed directly. The ICP can be retained in the quartz torch because the flow of gas between the two outermost tubes keeps the plasma away from the walls of the torch. A second flow of argon (around 1 liter per minute) is usually introduced between the central tube and the intermediate tube to keep the plasma away from the end of the central tube. A third flow (again usually around 1 liter per minute) of gas is introduced into the central tube of the torch.
=== Essendon: 2008-2012 === Prismall returned from injury towards the second half of the 2009 season for the Essendon Bombers and had an injury free return. He played 13 games for the club in 2009 and was a regular contributor, kicking five goals. In the 2010 season, Prismall was in and out of the Essendon team. His performances were not consistent and his ball skills were lacking. Towards the end of the season, however, his form improved considerably, despite the team's poor performances on the field. After a reconstruction on his right knee in 2008, he injured his left knee in the opening minutes of round 19, 2011 match against Collingwood and was out for the rest of the season. Prismall was delisted at the end of the 2012 season.
Sources: en.wikipedia.org
== External links == "Melanocortin Receptors: MC4". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. Archived from the original on 2016-03-03. Retrieved 2008-12-05. This article incorporates text from the United States National Library of Medicine, which is in the public domain.
== Name == Cold noodles in Chinese cuisine are referred to as liángmiàn (凉面, "chilled noodles"). The term lěngmiàn (冷面, "cold noodles") is mainly associated with Korean-style cold noodles (naengmyeon), which are popular in Northeast China, especially the Yanji-style cold noodles (延吉冷面), a dish of the ethnic Korean communities of the region. Although kǎolěngmiàn contains the word lěngmiàn, the dish is not directly derived from Korean cold noodles. Rather, it developed in Northeast China from starch noodle sheets used in the production of Korean-style cold noodles in the region. As these sheets began to be mass-produced and sold cheaply, street vendors used them to create a grilled snack cooked on charcoal stoves or iron griddles. Vendors commonly market the dish under names such as "Northeast grilled cold noodles" (东北烤冷面), "Heilongjiang grilled cold noodles" (黑龙江烤冷面), and sometimes "Harbin grilled cold noodles" (哈尔滨烤冷面), despite the dish not having originated in Harbin. It is also sometimes marketed as "Korean grilled cold noodles" (朝鲜烤冷面 / 韩国烤冷面) because of its association with Korean-style cold noodles (lěngmiàn) in the name, even though grilled cold noodles themselves did not originate in Korea.
=== Graphene aerogel === An aerogel made of graphene layers separated by carbon nanotubes was measured at 0.16 milligrams per cubic centimeter. A solution of graphene and carbon nanotubes in a mold is freeze-dried to dehydrate the solution, leaving the aerogel. The material has superior elasticity and absorption. It can recover completely after more than 90% compression, and absorb up to 900 times its weight in oil, at a rate of 68.8 grams per second.
== History == Dr Lal PathLabs was started in 1949, by the late S. K. Lal. Lal was a Junior Doctor in the British Indian Army and studied pathology from the Armed Forces Medical College in Pune, with additional training in pathology at Cook County Hospital in Chicago. The main operation of Dr Lal PathLabs deals with the performing of diagnosis and testing, including routine tests (including blood tests), specialized tests (e.g., viral and bacterial infection tests) and preventive screenings. In 2014, Dr Lal PathLabs acquired the APL Clinical Institute of Clinical Laboratory & Research Private Limited. Dr Lal PathLabs launched its IPO in 2015. The company got listed on BSE and NSE on 23 December 2015. In 2021, Dr Lal PathLabs acquired Suburban Diagnostics for an enterprise value of ₹925 crore in an all-cash deal.
R. Bruce Merrifield Award, American Peptide Society, 2015. Josef Rudinger Memorial Award (joint with Manfred Mutter), European Peptide Society, 2008. Burckhardt Helferich Prize for bioorganic chemistry, 2005. Vincent du Vigneaud Award, American Peptide Society, 2002. Max Planck Research Prize, Max Planck Society, 2001. Emil Fischer Medal, German Chemical Society, 1997.
Sources: en.wikipedia.org
As of 2005, India was the only country producing licit opium (opium gum) for both domestic use and export. Licit opium was produced also in Democratic People's Republic of Korea for domestic use, and in Japan for maintenance of the pertinent technology (small quantities). Opium poppies were grown principally for extraction of alkaloids (from poppy straw) in nine other countries: Australia, China, France, Hungary, Slovakia, Spain, the Republic of Macedonia, Turkey, and the United Kingdom. China ceased producing licit opium after 2001. Opium poppies grown principally for the seed crop, with licit poppy straw as a by-product, were produced in the Czech Republic, Serbia and Montenegro. Another six countries cultivated opium poppies solely for the poppy seed or horticultural purposes, without extraction of alkaloids from poppy straw: Austria, Estonia, Germany, Netherlands, Poland, and Ukraine. Illicit production of Polish heroin and other products derived from poppy straw is an ongoing problem in Poland, although it isn't as serious as in the 1980s, after poppies containing high levels of opioid alkaloids were banned in 1990s. The production of licit opium in India was in accord with terms of the 1961 Single Convention on Narcotic Drugs. After the opium was harvested, the plants were allowed to mature and harvested for poppy seeds. The sale of poppy seeds delivered a significant proportion of the income from the licit opium crop. Unknown fractions of both the opium harvest and the poppy straw residue from the poppy seed harvest were diverted to illicit uses.
In a clinical trial, the rate of systolic orthostatic hypotension was 21% versus 9% with placebo and the rate of diastolic orthostatic hypotension was 12% versus 4% with placebo in people with Parkinson's disease taking the ODT form of selegiline. The risk of hypotension is greater at the start of treatment and in the elderly (3% vs. 0% with placebo). The rate of hypotension or orthostatic hypotension with the selegiline patch was 2.2% versus 0.5% with placebo in clinical trials of people with depression. Significant orthostatic blood pressure changes (≥10 mm Hg decrease) occurred in 9.8% versus 6.7% with placebo, but most of these cases were asymptomatic and heart rate was unchanged. The rates of other orthostatic hypotension-related side effects in this population were dizziness or vertigo 4.9% versus 3.1% with placebo and fainting 0.5% versus 0.0% with placebo. It is said that orthostatic hypotension is rarely seen with the selegiline transdermal patch compared to oral MAOIs. Caution is advised against rapidly rising after sitting or lying, especially after prolonged periods or at the start of treatment, as this can result in fainting. Falls are of particular concern in the elderly. MAOIs like selegiline may lower blood pressure by increasing dopamine levels and activating dopamine receptors, by increasing levels of the false neurotransmitter octopamine, and/or by other mechanisms. Meta-analyses published in the 1990s found that the addition of selegiline to levodopa increased mortality in people with Parkinson's disease.
In all cases where β+ decay (positron emission) of a nucleus is allowed energetically, so too is electron capture allowed. This is a process during which a nucleus captures one of its atomic electrons, resulting in the emission of a neutrino:
==== MRGPRX2 mast cell receptor ==== Human mast-cell-specific G-protein-coupled receptor MRGPRX2 plays a key role in the recognition of pathogen associated molecular patterns (PAMPs) and initiating an antibacterial response. Binding of MRGPRX2 to competence stimulating peptide (CSP) 1, produced by Gram-positive bacteria, leads to signal transduction to a G protein and activation of the mast cell. Mast cell activation induces the release of antibacterial mediators including ROS, TNF-α and PRGD2 which institute the recruitment of other immune cells to inhibit bacterial growth and biofilm formation.
Early bulbs were laboriously assembled by hand. After automatic machinery was developed, the cost of bulbs fell. Until 1910, when Libbey's Westlake machine went into production, bulbs were generally produced by a team of three workers (two gatherers and a master gaffer) blowing the bulbs into wooden or cast-iron molds, coated with a paste. Around 150 bulbs per hour were produced by the hand-blowing process in the 1880s at Corning Glass Works. The Westlake machine, developed by Libbey Glass, was based on an adaptation of the Owens-Libbey bottle-blowing machine. Corning Glass Works soon began developing competing automated bulb-blowing machines, the first of which to be used in production was the E-Machine.
Sources: en.wikipedia.org
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.
It is classified as a PPARδ agonist on the WADA Prohibited List. Anti-doping laboratories can detect it and its metabolites in urine. Its use is banned in competition and usually out of competition.
Rodent studies reported increased tumor incidence at multiple sites. The human relevance remains uncertain, but the findings contributed to discontinuation of development. No long-term human cancer data are available.
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.